Alkermes plc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
ALKS$46.47+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| (In thousands) | |||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net income | $241,664 | $367,070 | $355,757 |
| Adjustments to reconcile net income to cash flows from operating activities: | |||
| Depreciation and amortization | 27,165 | 28,533 | 74,927 |
| Share-based compensation expense | 98,716 | 96,637 | 100,905 |
| Deferred income taxes | 28,774 | 40,522 | (99,902) |
| Other non-cash charges | 5,311 | 4,512 | 6,329 |
| Changes in assets and liabilities: | |||
| Receivables | 50,503 | (52,052) | (44,510) |
| Contract assets | 4,990 | (4,284) | 8,223 |
| Inventory | (14,061) | 3,091 | (2,712) |
| Prepaid expenses and other assets | 852 | 2,254 | (34,847) |
| Right-of-use assets | 7,549 | 7,215 | 15,387 |
| Accounts payable and accrued expenses | 100,893 | (57,967) | 23,009 |
| Accrued sales discounts, allowances and reserves | (25,326) | 8,811 | 11,526 |
| Contract liabilities | (1,249) | (3,525) | (5,926) |
| Operating lease liabilities | (10,320) | (10,123) | (16,147) |
| Other long-term liabilities | 5,293 | 8,430 | 9,334 |
| Cash flows provided by operating activities | 520,754 | 439,124 | 401,353 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Additions of property, plant and equipment | (40,420) | (33,484) | (48,048) |
| Proceeds from the sale of property, plant and equipment | 1,086 | 461 | 354 |
| Return of Fountain Healthcare Partners II, L.P. investment | — | 43 | — |
| Proceeds from the sale of the Athlone Facility | 1,708 | 97,933 | — |
| Purchases of investments | (364,369) | (486,547) | (254,471) |
| Sales and maturities of investments | 697,492 | 310,286 | 355,522 |
| Cash flows provided by (used in) investing activities | 295,497 | (111,308) | 53,357 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Cash transferred to Mural Oncology plc at separation | — | — | (275,000) |
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements | 43,411 | 27,572 | 16,760 |
| Employee taxes paid related to net share settlement of equity awards | (31,032) | (29,637) | (28,474) |
| Payment for the repurchase of ordinary shares | — | (200,282) | — |
| Prepayment of long-term debt | — | (289,542) | — |
| Principal payments of long-term debt | — | (2,250) | (3,000) |
| Cash flows provided by (used in) financing activities | 12,379 | (494,139) | (289,714) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 828,630 | (166,323) | 164,996 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period | 291,146 | 457,469 | 292,473 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period | $1,119,776 | $291,146 | $457,469 |
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||
| Cash and cash equivalents | $388,570 | $291,146 | $457,469 |
| Restricted cash | 731,206 | — | — |
| Total cash, cash equivalents and restricted cash | $1,119,776 | $291,146 | $457,469 |
| SUPPLEMENTAL CASH FLOW DISCLOSURE: | |||
| Cash paid for interest | $— | $23,010 | $22,748 |
| Cash paid for taxes | $5,237 | $2,592 | $44,243 |
| Non-cash investing and financing activities: | |||
| Purchased capital expenditures included in accounts payable and accrued expenses | $3,128 | $2,254 | $2,645 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.